Petrelintide PETR

An experimental long-acting weight-loss drug in human trials, used alone or combined with other treatments for obesity. Early results show meaningful weight loss with a good tolerability record, though it remains unapproved.

Also known as ZP8396

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Molecular Structure of C₁₈₅H₃₀₅N₄₉O₆₁

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C185H305N49O61
Molar mass: 4192
PubChem CID: 172915807

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial dosing under evaluation

Reported range Phase II trials: doses still being optimized, subcutaneous weekly dosing

Route Subcutaneous injection

Frequency Once weekly

Duration Trial durations of several months

Investigational amylin analog (Zealand Pharma) for obesity; not an approved product.

Where this comes from Published Phase II clinical trial data (Zealand Pharma)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.